Nilotinib Stada (Nilotinib)

Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein produced by the Philadelphia chromosome translocation in CML cells. By blocking this enzyme, nilotinib prevents downstream signaling that leads to uncontrolled cell proliferation, inducing apoptosis and reducing the number of malignant leukocytes. This targeted mechanism distinguishes it from conventional chemotherapy.

The specific dose of nilotinib is determined by the prescribing physician based on the patient’s disease phase, overall health, and concomitant medications. Dosage adjustments may be required for hepatic impairment, drug interactions, or adverse reactions. Patients should follow the exact regimen provided in their prescription and consult their oncologist for any changes.

Nilotinib is classified as contraindicated in pregnancy unless the potential benefit justifies the risk, because it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation. Limited data exist for breastfeeding, and the drug is generally not recommended while nursing. Consultation with a specialist is essential before any exposure.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team will then confirm pricing, availability, shipping terms—including any necessary temperature control—and assist with import documentation.

The primary alternative to nilotinib in CML therapy is imatinib, the first‑generation BCR‑ABL inhibitor. Nilotinib, a second‑generation agent, offers higher potency and can be effective in patients who are resistant or intolerant to imatinib. It typically achieves faster and deeper molecular responses, but may carry a different safety profile, including a higher risk of QT prolongation, requiring careful cardiac monitoring.

Nilotinib tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Do not refrigerate or freeze the product. Keep the medication out of reach of children and dispose of any unused tablets according to local regulations or pharmacy guidelines.

Nilotinib is taken orally, usually twice daily on an empty stomach, with at least one hour before or two hours after a meal. The tablets should be swallowed whole with a glass of water; they must not be chewed, crushed, or dissolved. Patients should adhere to the prescribed schedule and avoid taking antacids or supplements that could interfere with absorption unless directed by their physician.

The most critical adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, and severe hepatotoxicity manifested by marked liver enzyme elevations. Hematologic toxicities such as neutropenia and thrombocytopenia may also occur, increasing infection or bleeding risk. Prompt reporting of chest pain, palpitations, jaundice, or unexplained bruising to a healthcare professional is essential for timely management.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients. Individuals with a history of significant QT prolongation, uncontrolled cardiac arrhythmias, or severe hepatic impairment should avoid the drug unless a specialist determines that benefits outweigh risks. It is also not recommended for pregnant or breastfeeding women without a compelling medical justification. Always consult a qualified oncologist before initiating therapy.